Detection of Lung Cancer by Plasma Lipids (ELAID)

Peking University

Status: Completed

Conditions: Early-Stage Lung Cancer

Treatments: Diagnostic Test: Plasma lipids

Study type: Observational

Funder types: Other

Identifiers

NCT04287712

2018PHB233-01

Details and patient eligibility

About

There are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. We try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

Full description

All plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. Then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. Finally, a detection model was established based on the 9 lipids.

Enrollment: 558 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. pulmonary nodules or opacity
2. plan to receive surgery

Exclusion criteria

1. history of other malignancies
2. received anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery

Trial design

558 participants in 1 patient group

Participants received surgery

Description:

Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.

Treatment:

Diagnostic Test: Plasma lipids